VSTM vs. VNDA, XOMA, EBS, LXRX, RIGL, RGLS, OPK, INVA, IRWD, and NLTX
Should you be buying Verastem stock or one of its competitors? The main competitors of Verastem include Vanda Pharmaceuticals (VNDA), XOMA (XOMA), Emergent BioSolutions (EBS), Lexicon Pharmaceuticals (LXRX), Rigel Pharmaceuticals (RIGL), Regulus Therapeutics (RGLS), OPKO Health (OPK), Innoviva (INVA), Ironwood Pharmaceuticals (IRWD), and Neoleukin Therapeutics (NLTX). These companies are all part of the "pharmaceutical preparations" industry.
Vanda Pharmaceuticals (NASDAQ:VNDA) and Verastem (NASDAQ:VSTM) are both small-cap medical companies, but which is the better business? We will contrast the two businesses based on the strength of their community ranking, media sentiment, analyst recommendations, profitability, valuation, institutional ownership, dividends, risk and earnings.
Verastem received 63 more outperform votes than Vanda Pharmaceuticals when rated by MarketBeat users. However, 68.55% of users gave Vanda Pharmaceuticals an outperform vote while only 65.25% of users gave Verastem an outperform vote.
In the previous week, Verastem had 18 more articles in the media than Vanda Pharmaceuticals. MarketBeat recorded 24 mentions for Verastem and 6 mentions for Vanda Pharmaceuticals. Vanda Pharmaceuticals' average media sentiment score of 0.16 beat Verastem's score of 0.12 indicating that Verastem is being referred to more favorably in the news media.
Vanda Pharmaceuticals has a beta of 0.71, meaning that its stock price is 29% less volatile than the S&P 500. Comparatively, Verastem has a beta of 0.58, meaning that its stock price is 42% less volatile than the S&P 500.
Vanda Pharmaceuticals has higher revenue and earnings than Verastem. Vanda Pharmaceuticals is trading at a lower price-to-earnings ratio than Verastem, indicating that it is currently the more affordable of the two stocks.
Verastem has a consensus target price of $26.50, suggesting a potential upside of 559.20%. Given Vanda Pharmaceuticals' higher possible upside, analysts clearly believe Verastem is more favorable than Vanda Pharmaceuticals.
Verastem has a net margin of 0.00% compared to Verastem's net margin of -2.75%. Verastem's return on equity of -0.90% beat Vanda Pharmaceuticals' return on equity.
88.1% of Vanda Pharmaceuticals shares are held by institutional investors. Comparatively, 88.4% of Verastem shares are held by institutional investors. 7.7% of Vanda Pharmaceuticals shares are held by company insiders. Comparatively, 2.2% of Verastem shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.
Summary
Verastem beats Vanda Pharmaceuticals on 9 of the 17 factors compared between the two stocks.
Get Verastem News Delivered to You Automatically
Sign up to receive the latest news and ratings for VSTM and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding VSTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Verastem Competitors List
Related Companies and Tools
